Oruka Therapeutics

Company snapshot

Advancing novel biologics that aim to offer the greatest possible freedom from disease to people with plaque psoriasis and other associated conditions

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Oruka Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Oruka Therapeutics.

1. Jun 5, 2026 Clinical update

   ORKA-001, Placebo for ORKA-001 — Phase 2

2. Jun 5, 2026 Clinical update

   ORKA-001 Induction Dose — Phase 2

3. May 26, 2026 Clinical update

   ORKA-001 — Phase 1

4. May 23, 2026 Clinical update

   ORKA-001 — Phase 2

5. May 23, 2026 Clinical update

   ORKA-002 — Phase 2

View all clinical trial activity →

• What is Oruka Therapeutics?

  Oruka Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker ORKA. Primary therapeutic focus areas include Plaque Psoriasis, Moderate-to-Severe Plaque Psoriasis. NovaPharmaNews links 6 clinical program(s), 0 drug profile(s), and 0 pate

• Is Oruka Therapeutics publicly traded?

  Yes. Oruka Therapeutics is listed with ticker ORKA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Oruka Therapeutics develop or market?

  We link 3 drug profile(s) where Oruka Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/oruka-therapeutics#company-drugs.

• What are the latest developments for Oruka Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Oruka Therapeutics focus on?

  Oruka Therapeutics focuses on Plaque Psoriasis, Moderate-to-Severe Plaque Psoriasis based on our analysis of their pipeline programs and drug development activities.